Targeting differentiation blockade in AML: New hope from cell-surface-based CRISPR screens

Rui Su; Ying Qing; Jianjun Chen

doi:10.1016/j.stem.2021.03.006

Targeting differentiation blockade in AML: New hope from cell-surface-based CRISPR screens

Cell Stem Cell. 2021 Apr 1;28(4):585-587. doi: 10.1016/j.stem.2021.03.006.

Authors

Rui Su¹, Ying Qing², Jianjun Chen³

Affiliations

¹ Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
² Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
³ Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; City of Hope Comprehensive Cancer Center, City of Hope, Duarte, CA 91010, USA; Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA 91010, USA. Electronic address: jianchen@coh.org.

PMID: 33798415
DOI: 10.1016/j.stem.2021.03.006

Abstract

Accumulation of undifferentiated myeloid progenitors is a hallmark of AML, and targeting differentiation blockade represents a promising therapeutic strategy for AML. In this issue of Cell Stem Cell, Wang et al. (2021) conducted surface antigen-guided CRISPR screening and identified ZFP36L2 as a myeloid leukemia differentiation regulator and new therapeutic target.

Publication types

Comment

MeSH terms

Antigens, Surface
Cell Differentiation
Clustered Regularly Interspaced Short Palindromic Repeats* / genetics
Hematopoiesis
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics

Substances

Antigens, Surface

Abstract

Publication types

MeSH terms

Substances

Grants and funding